PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Corcept Therapeutics Incorporated (CORT)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US2183521028

CUSIP

218352102

Sector

Healthcare

IPO Date

Apr 14, 2004

Highlights

Market Cap

$5.88B

EPS (TTM)

$1.26

PE Ratio

44.52

PEG Ratio

0.61

Total Revenue (TTM)

$628.56M

Gross Profit (TTM)

$618.75M

EBITDA (TTM)

$144.55M

Year Range

$20.84 - $61.66

Target Price

$74.90

Short %

25.19%

Short Ratio

17.04

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
CORT vs. BOOT CORT vs. ASY.PA CORT vs. AXSM CORT vs. COST CORT vs. AVAV CORT vs. AMPH CORT vs. IOVA CORT vs. LNTH CORT vs. ETN CORT vs. TXMD
Popular comparisons:
CORT vs. BOOT CORT vs. ASY.PA CORT vs. AXSM CORT vs. COST CORT vs. AVAV CORT vs. AMPH CORT vs. IOVA CORT vs. LNTH CORT vs. ETN CORT vs. TXMD

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Corcept Therapeutics Incorporated, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%20.00%40.00%60.00%80.00%100.00%120.00%JuneJulyAugustSeptemberOctoberNovember
100.86%
12.92%
CORT (Corcept Therapeutics Incorporated)
Benchmark (^GSPC)

Returns By Period

Corcept Therapeutics Incorporated had a return of 72.17% year-to-date (YTD) and 120.68% in the last 12 months. Over the past 10 years, Corcept Therapeutics Incorporated had an annualized return of 33.84%, outperforming the S&P 500 benchmark which had an annualized return of 11.16%.


CORT

YTD

72.17%

1M

14.31%

6M

100.86%

1Y

120.68%

5Y (annualized)

33.90%

10Y (annualized)

33.84%

^GSPC (Benchmark)

YTD

24.72%

1M

1.67%

6M

12.93%

1Y

30.55%

5Y (annualized)

13.88%

10Y (annualized)

11.16%

Monthly Returns

The table below presents the monthly returns of CORT, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-35.04%11.37%7.19%-7.42%29.37%7.69%19.02%-8.71%31.10%5.81%72.17%
202312.56%-8.88%3.98%4.02%4.26%-5.28%14.52%28.45%-16.76%3.06%-9.29%27.52%59.92%
2022-5.20%18.75%1.03%-4.48%-3.11%14.11%20.52%-9.91%-0.70%11.54%-11.61%-19.66%2.58%
20218.03%-11.00%-5.41%-4.20%-5.22%1.85%-5.59%2.46%-7.52%-8.54%16.67%-5.71%-24.31%
20204.71%-0.39%-5.78%6.48%19.59%11.10%-11.12%-15.05%37.05%-3.59%34.92%15.55%116.20%
2019-16.32%11.54%-5.85%5.45%-21.00%14.01%0.99%11.99%12.09%3.22%-12.06%-5.69%-9.43%
201827.44%-34.00%8.29%1.40%10.91%-15.03%-16.48%14.39%-6.66%-16.19%18.55%-4.09%-26.02%
2017-2.07%26.44%21.91%-12.96%18.55%4.33%5.68%33.68%15.78%2.02%-8.89%0.67%148.76%
2016-26.71%4.66%22.51%1.92%24.74%-8.24%6.23%-8.10%21.95%6.77%20.89%-13.47%45.78%
2015-3.00%13.75%69.18%3.04%6.07%-1.80%-16.14%-0.79%-24.80%-1.86%43.09%-5.68%66.00%
20147.17%-4.65%32.93%1.38%-48.87%23.89%-14.64%15.48%-2.90%21.27%-6.77%-0.99%-6.54%
201351.75%-24.65%22.32%-11.50%2.82%-4.95%21.97%-21.33%-4.22%6.29%27.22%49.30%124.48%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current risk-adjusted rank of CORT is 88, placing it in the top 12% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of CORT is 8888
Combined Rank
The Sharpe Ratio Rank of CORT is 9292
Sharpe Ratio Rank
The Sortino Ratio Rank of CORT is 8484
Sortino Ratio Rank
The Omega Ratio Rank of CORT is 8888
Omega Ratio Rank
The Calmar Ratio Rank of CORT is 9494
Calmar Ratio Rank
The Martin Ratio Rank of CORT is 8282
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Corcept Therapeutics Incorporated (CORT) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for CORT, currently valued at 2.21, compared to the broader market-4.00-2.000.002.004.002.212.54
The chart of Sortino ratio for CORT, currently valued at 2.50, compared to the broader market-4.00-2.000.002.004.002.503.40
The chart of Omega ratio for CORT, currently valued at 1.39, compared to the broader market0.501.001.502.001.391.47
The chart of Calmar ratio for CORT, currently valued at 3.19, compared to the broader market0.002.004.006.003.193.66
The chart of Martin ratio for CORT, currently valued at 6.72, compared to the broader market0.0010.0020.0030.006.7216.26
CORT
^GSPC

The current Corcept Therapeutics Incorporated Sharpe ratio is 2.21. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Corcept Therapeutics Incorporated with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.

Rolling 12-month Sharpe Ratio0.000.501.001.502.002.503.003.50JuneJulyAugustSeptemberOctoberNovember
2.21
2.54
CORT (Corcept Therapeutics Incorporated)
Benchmark (^GSPC)

Dividends

Dividend History


Corcept Therapeutics Incorporated doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-20.00%-15.00%-10.00%-5.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-6.17%
-0.88%
CORT (Corcept Therapeutics Incorporated)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Corcept Therapeutics Incorporated. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Corcept Therapeutics Incorporated was 94.28%, occurring on Oct 13, 2006. Recovery took 2670 trading sessions.

The current Corcept Therapeutics Incorporated drawdown is 6.17%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-94.28%Apr 15, 2004630Oct 13, 20062670May 26, 20173300
-61.65%Jan 30, 2018336May 31, 2019389Dec 14, 2020725
-45.91%Feb 9, 2021245Jan 27, 2022380Aug 3, 2023625
-37.57%Sep 15, 202395Jan 31, 202487Jun 5, 2024182
-23.89%Oct 6, 201752Dec 19, 201714Jan 10, 201866

Volatility

Volatility Chart

The current Corcept Therapeutics Incorporated volatility is 16.16%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%JuneJulyAugustSeptemberOctoberNovember
16.16%
3.96%
CORT (Corcept Therapeutics Incorporated)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Corcept Therapeutics Incorporated over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of Corcept Therapeutics Incorporated compared to its peers in the Biotechnology industry.


PE Ratio
200.0400.0600.044.5
The chart displays the price to earnings (P/E) ratio for CORT in comparison to other companies of the Biotechnology industry. Currently, CORT has a PE value of 44.5. This PE ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.
PEG Ratio
-1,000.0-800.0-600.0-400.0-200.00.00.6
The chart displays the price to earnings to growth (PEG) ratio for CORT in comparison to other companies of the Biotechnology industry. Currently, CORT has a PEG value of 0.6. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Corcept Therapeutics Incorporated.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items